Saad Z. Usmani, MBBS, MD, MBA, FACP, FRCP, FASCO

Saad Z. Usmani, MBBS, MD, MBA, FACP, FRCP, FASCO, joined Memorial Sloan Kettering Cancer Center in 2021 as chief of the Myeloma Service and holds a faculty position as a professor of clinical medicine at Weill Cornell Medical College, Cornell University, in New York, NY.

Dr Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed his residency in internal medicine at DMC Sinai-Grace Hospital/Wayne State University in Detroit, MI, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington. In 2010, he joined the University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy in Little Rock as director of developmental therapeutics. In 2013, Dr Usmani was recruited to the Atrium Health Levine Cancer Institute as the inaugural division chief of plasma cell disorders and director of clinical research for hematologic malignancies, where he built an internationally renowned multiple myeloma (MM) program.

He is board certified in internal medicine, medical oncology, and hematology. Dr Usmani is a fellow of the American College of Physicians, the Royal College of Physicians (in the United Kingdom), and the American Society of Clinical Oncology (ASCO). He also holds membership and leadership roles on national and international committees, including with the International Myeloma Working Group (scientific advisory board member), the ALLIANCE Myeloma Committee (chair), the American Society of Hematology, ASCO, the International Myeloma Society (board member), the American Society for Transplantation and Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Additionally, Dr Usmani has served as vice chair of the SWOG Barlogie-Salmon Myeloma Committee, as chair of the American Society of Hematology Scientific Committee on Plasma Cell Neoplasia, and on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders.

Dr Usmani has received several international awards and honors in recognition of his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research in Hematology, the Multiple Myeloma Excellence in Clinical Research Award (World Congress on Controversies in Multiple Myeloma [also known as COMy]), The Leukemia & Lymphoma Society (currently known as Blood Cancer United) Scholar in Clinical Research Award, the International Myeloma Society Bart Barlogie Clinical Investigator Award in Clinical and Translational Research, The Leukemia & Lymphoma Society Career Development Program Achievement Award, the Giants of Cancer Care Award, and the COMy Jean-Luc Harousseau Award.

Active in clinical and translational research, Dr Usmani has research interests that focus on plasma cell disorders—in particular, high-risk MM. He has led the clinical development of several novel therapies, including anti-CD38 monoclonal antibodies, bsAbs, and CAR T-cell therapies, resulting in regulatory approvals in MM. Dr Usmani has authored/coauthored more than 380 peer-reviewed research manuscripts in The New England Journal of Medicine, The Lancet, Nature Medicine, the Journal of Clinical Oncology, Cancer Cell, The Lancet Oncology, Blood, and Leukemia, among others.